Diuretic Resistance in Heart-Kidney Syndrome: Role of Natriuretic Peptides and GLP-1
Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
Quick Facts
What This Study Found
Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
Key Numbers
Up to one-third of heart failure patients develop diuretic resistance. Congestion drives most heart failure hospitalizations.
How They Did This
Study design and methodology detailed in the full publication.
Why This Research Matters
These findings are relevant to the growing population of patients using or considering peptide-based therapies.
The Bigger Picture
This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.
What This Study Doesn't Tell Us
Study limitations discussed in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to existing evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug
- Evidence Grade:
- Evidence assessment based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.
- Published In:
- Frontiers in cardiovascular medicine, 12, 1731305 (2025)
- Authors:
- Aletras, Georgios(2), Bachlitzanaki, Maria(2), Stratinaki, Maria(3), Foukarakis, Emmanuel, Petrakis, Ioannis, Pantazis, Yannis, Hamilos, Michalis, Stylianou, Kostas
- Database ID:
- RPEP-09851
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this study mean for patients?
Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
How reliable are these findings?
Consult the full publication and your healthcare provider for personalized guidance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09851APA
Aletras, Georgios; Bachlitzanaki, Maria; Stratinaki, Maria; Foukarakis, Emmanuel; Petrakis, Ioannis; Pantazis, Yannis; Hamilos, Michalis; Stylianou, Kostas. (2025). Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.. Frontiers in cardiovascular medicine, 12, 1731305. https://doi.org/10.3389/fcvm.2025.1731305
MLA
Aletras, Georgios, et al. "Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.." Frontiers in cardiovascular medicine, 2025. https://doi.org/10.3389/fcvm.2025.1731305
RethinkPeptides
RethinkPeptides Research Database. "Diuretic resistance in cardiorenal syndrome: mechanisms, mon..." RPEP-09851. Retrieved from https://rethinkpeptides.com/research/aletras-2025-diuretic-resistance-in-cardiorenal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.